Drug General Information |
Drug ID |
D0Y8NO
|
Former ID |
DNC007551
|
Drug Name |
RTI-5989-31
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C23H29NO
|
Canonical SMILES |
CC1C2CCCC1(CCN2CCC3=CC=CC=C3)C4=CC(=CC=C4)O
|
InChI |
1S/C23H29NO/c1-18-22-11-6-13-23(18,20-9-5-10-21(25)17-20)14-16-24(22)15-12-19-7-3-2-4-8-19/h2-5,7-10,17-18,22,25H,6,11-16H2,1H3
|
InChIKey |
FJRARMQVERMSNJ-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Delta-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
Kappa-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
Estrogen signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Enkephalin release
|
Opioid proenkephalin pathway
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
Reactome
|
Peptide ligand-binding receptors
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
G alpha (i) signalling events
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
Peptide GPCRs
|
GPCR ligand binding
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
Opioid Signalling
|
GPCR downstream signaling
|
References |
REF 1 | J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. |